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Aims The aim of this study was to examine whether left ventricular ejection fraction (LVEF) modified efficacy and safety
of dapagliflozin 10 mg compared with placebo in the 4744 patients with LVEF≤40% randomized in the Dapagliflozin
And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF).
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Methods
and results
We examined whether LVEF, analysed categorically or continuously, modified the effect of dapagliflozin. The primary
efficacy outcome was the composite of a worsening heart failure (HF) event (unplanned HF hospitalization/an urgent
HF visit requiring intravenous therapy) or cardiovascular death. Mean LVEF was 31.1% and LVEF categories analysed
were: <26% (n = 1143), 26–30% (n = 1018), 31–35% (n = 1187), and >35% (n = 1396). Each 5% decrease in LVEF
was associated with a higher risk of the primary outcome [hazard ratio (HR) 1.18; 95% confidence interval (CI)
1.13–1.24]. The benefit of dapagliflozin was consistent across the spectrum of LVEF: the dapagliflozin vs. placebo
HR was 0.75 (95% CI 0.59–0.95) for LVEF <26%, 0.75 (0.57–0.98) for LVEF 26–30%, 0.67 (0.51–0.89) for LVEF
31–35%, and 0.83 (0.63–1.09) for LVEF>35% (P for interaction = 0.762). Similarly, the effect of dapagliflozin on
the components of the primary endpoint was not modified by baseline LVEF (P for interaction for cardiovascular
death = 0.974, and for worsening HF = 0.161). Safety of dapagliflozin was also consistent across the range of LVEF
and neither efficacy nor safety were modified by diabetes status.
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Conclusion Left ventricular ejection fraction was a significant predictor of hospitalization and mortality in patients with HF with
reduced ejection fraction but did not modify the beneficial effect of dapagliflozin, overall or separately, in patients
with and without diabetes.
Clinical Trial Registration: ClinicalTrials.gov Identifier NCT03036124
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Introduction
Left ventricular ejection fraction (LVEF) is the most commonly
used measure of left ventricular systolic function. Not only does
it help diagnose heart failure (HF) with reduced ejection fraction
(HFrEF), and distinguish between patients with HFrEF and HF with
preserved ejection fraction (HFpEF), but it is also an important
predictor of morbidity and mortality.1,2 Both the risk of HF
hospitalization and cardiovascular mortality are higher in patients
with lower LVEF.1
In the Dapagliflozin And Prevention of Adverse-outcomes in
Heart Failure trial (DAPA-HF), 4744 patients with HF and a LVEF
≤40% were randomized to receive either the sodium–glucose
co-transporter 2 (SGLT2) inhibitor dapagliflozin or matching
placebo.3 Patients allocated to dapagliflozin had a 26% lower risk of
the primary outcome of a worsening HF event (HF hospitalization
or an urgent HF visit requiring intravenous therapy) or cardiovas-
cular death, compared with placebo. In the present report, we eval-
uated whether LVEF at baseline modified the effects of dapagliflozin
in the patients enrolled in DAPA-HF, overall and in participants with
and without diabetes separately.
Methods
Patients and study design
The design and primary results of the DAPA-HF trial are published.3,4
The trial was approved by ethics committees at 410 participating cen-
tres in 20 countries and all participants gave written informed consent.
Patients were eligible at screening if they were at least 18 years
of age, were in New York Heart Association (NYHA) functional
classes II to IV, had a LVEF ≤40%, and an elevated N-terminal pro
brain natriuretic peptide (NT-proBNP, ≥600 pg/mL or ≥400 pg/mL if
hospitalized for HF within the previous 12 months). In patients with
atrial fibrillation or atrial flutter on their baseline electrocardiogram,
NT-proBNP had to be ≥900 pg/mL, regardless of history of hospital-
ization for HF. Patients were required to receive standard HF drug and
device therapy, including an angiotensin-converting enzyme inhibitor
(ACEI), an angiotensin receptor blocker (ARB) or an angiotensin
receptor–neprilysin inhibitor (ARNI), along with a beta-blocker and
mineralocorticoid receptor antagonist (MRA), unless contraindicated
or not tolerated. Glucose-lowering therapy (including insulin) was con-
tinued in patients with diabetes, with adjustments made, as required,
during follow-up.
Left ventricular ejection fraction was required to have been
measured within 12 months of enrolment, by echocardiography,
radionuclide ventriculography, contrast angiography, or cardiac mag-
netic resonance imaging. Patients without a LVEF measurement within .
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. the previous 12 months were required to have LVEF measured at the
time of enrolment.
Key exclusion criteria included symptoms of hypotension or systolic
blood pressure (SBP) <95 mmHg, estimated glomerular filtration rate
(eGFR) <30 mL/min/1.73 m2 and type 1 diabetes.
Patients were randomized to receive either dapagliflozin (10 mg
once daily) or matching placebo in a 1:1 ratio. Randomization was strat-
ified based on either history of diabetes or on a glycated haemoglobin
level of ≥6.5% at enrolment (but for analyses, baseline diabetes was
defined as a medical history of diabetes or a glycated haemoglobin level
of ≥6.5% at both the enrolment and randomization visits).
The median duration of follow-up was 18.2 months (minimum of
5 days and maximum of 27.8 months).
Outcomes
The primary outcome was a composite of a worsening HF event
(an unplanned hospitalization for HF or an urgent HF visit requiring
intravenous therapy) or cardiovascular death.
The first secondary outcome was the composite of hospitalization
for HF or cardiovascular death. Other secondary outcomes included
a composite of the total number of hospitalizations for HF (first and
repeat) and cardiovascular death, and change from baseline to 8 months
in the total symptom score (TSS) of the Kansas City Cardiomyopathy
Questionnaire (KCCQ).5 The KCCQ is scored from 0 to 100 with
higher scores indicating better status and a change of ≥5 points is
regarded as a clinically meaningful change. A further secondary end-
point was a composite of worsening renal function, including: (i) a sus-
tained decline in eGFR of ≥50%; (ii) end-stage renal disease – defined
as a sustained (≥28 day) eGFR of <15 mL/min/1.73 m2, sustained dial-
ysis or renal transplantation; or (iii) renal death. Lastly, death from
any cause was also analysed. Safety outcomes included serious adverse
events, adverse events leading to treatment discontinuation and other
adverse events of special interest (adverse events related to volume
depletion, renal adverse events, major hypoglycaemic episodes, bone
fractures, diabetic ketoacidosis, amputations). Fournier’s gangrene and
laboratory findings of note.
Statistical analysis
In this analysis, patients were divided into four LVEF categories, similar
to those used in prior analyses and reflective of clinical practice, namely:
(i) <26%; (ii) 26–30%; (iii) 31–35%; and (iv) >35%.1,6,7 Baseline char-
acteristics are reported for each LVEF category as means± standard
deviation, median with interquartile range and proportions, as appro-
priate. A non-parametric Wilcoxon-type rank sum test and chi-square
tests were used for continuous and categorical variables, respectively.
The effect of dapagliflozin, compared to placebo, on each out-
come across the different LVEF categories was examined using Cox
regression. Event rates per 100 person-years and hazard ratios (HRs)
adjusted for previous HF hospitalization (except for all-cause death and
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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replaced by baseline eGFR for the renal outcomes) and stratified by
diabetes status are reported for each LVEF category. The proportional
hazards assumption was fulfilled for all major outcomes. The relation-
ship between LVEF as a continuous variable, and the risk of each major
clinical outcome, was also examined in restricted cubic spline analyses.
LVEF was modelled as a fractional polynomial to assess its interaction as
a continuous variable with treatment and displayed as a graph using the
mfpi function in Stata.8 The interaction between LVEF and treatment
on change in KCCQ-TSS at 8 months was tested in a linear regression
model with interaction between LVEF and treatment tested for using
the Wald method. The proportion of patients experiencing a 5-point
increase, and a 5-point decrease, in KCCQ-TSS at 8 months was exam-
ined in a logistic regression model, with the interaction term between
LVEF and treatment described using the Wald test. The HR per 5-point
decrease in baseline LVEF was calculated for the primary outcome and
its components, the composite outcome of cardiovascular death or
hospitalization for HF, hospitalization for HF and all-cause death, and
was adjusted for treatment and previous HF hospitalization (except
for all-cause death). All models were stratified by diabetes status as
specified.
All analyses were conducted using Stata version 16 (Stata Corp.,
College Station, TX, USA). A P-value of <0.05 was considered statis-
tically significant.
Results
Left ventricular ejection fraction ranged from 2% to 40% (although
one patient had a LVEF of 45%). The mean and median LVEF
were 31.1± 6.8% and 32% (IQR 26–37%), respectively. There
were 1143 patients with a LVEF <26%, 1018 patients with a LVEF
between 26% and 30%, 1187 with a LVEF between 31% and 35%,
and 1396 patients had a LVEF >35%.
Patient characteristics
As shown in Table 1, patients with a lower LVEF were younger
(mean 64 years in the lowest vs. 68 years in the highest LVEF
category), more likely to be male, less likely to be from Europe
or of white race, compared to patients with a higher LVEF. Fewer
patients with a lower LVEF had hypertension, diabetes, a previous
myocardial infarction, or atrial fibrillation. A higher proportion of
patients in the lowest LVEF category had a non-ischaemic aetiology
and more had a previous hospitalization for HF. Conversely, there
was no significant difference in median KCCQ-TSS score, or in the
proportion of patients in NYHA class II vs. III/IV, across the LVEF
categories. Patients with a lower LVEF had a higher NT-proBNP
level (median 1827 pg/mL in the lowest vs. 1275 pg/mL in the
highest LVEF category) and higher creatinine concentration. When
patients with and without diabetes were examined separately,
those with diabetes more often had a history of hypertension and
myocardial infarction (and an ischaemic aetiology), as well as worse
NYHA class, higher NT-proBNP and lower eGFR, compared to
participants without diabetes, across the range of LVEF (online
supplementary Table S1).
A greater proportion of patients with low LVEF were prescribed
diuretics. Use of sacubitril/valsartan, a MRA, digoxin, cardiac resyn-
chronization therapy and an implantable cardioverter-defibrillator
increased with decreasing LVEF, whereas the opposite trend was ..
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.. observed with an ACEI or ARB. These patterns were similar in
patients with and without diabetes and according to randomization
arm (online supplementary Table S1 and Table S4).
Among patients with diabetes at baseline, there was no signifi-
cant difference in the use of specific glucose-lowering medications
and insulin across the LVEF categories (Table 1 and online supple-
mentary Table S1).
Relationship between baseline left
ventricular ejection fraction
and hospitalization and mortality
outcomes
The rate of the primary outcome in placebo-treated patients in
the lowest LVEF category was 20.7 [95% confidence interval (CI)
17.7–24.1] per 100 patient-years, compared with 11.9 (9.9–14.3)
per 100 patient-years in patients in the highest LVEF category
(Table 2). The corresponding rates of the primary outcome in
patients with diabetes in the lowest and highest LVEF categories
were 26.8 (95% CI 21.8–33.0) and 14.6 (95% CI 11.5–18.6)
per 100 patient-years, respectively. In participants without dia-
betes these rates were 16.1 (95% CI 12.8–20.3) and 9.5 (95% CI
7.1–12.6) per 100 patient-years, respectively (online supplemen-
tary Table S2 and Figure S4).
As illustrated in Figure 1 and online supplementary Figure S3,
the risk of the clinical outcomes of interest increased as LVEF
decreased. Table 3 shows that each 5-point decrease in LVEF was
associated with an 18% higher risk of the primary outcome (HR
1.18, 95% CI 1.13–1.24) in the overall cohort. Corresponding HR
for a 5-point decrease in LVEF in participants with diabetes was
1.20 (95% CI 1.12–1.27) compared to 1.17 (95% CI 1.10–1.26)
in patients without diabetes.
In the overall population, the increment in risk of cardiovascular
death was 20% per 5-point decrease in LVEF (HR 1.20, 95% CI
1.13–1.28) with a similar increment in risk for an episode of
worsening HF (HR 1.20, 95% CI 1.14–1.27). The HR for all-cause
death was 1.13 (95% CI 1.07–1.20). The increase in HR per 5-point
decrease in LVEF for each of the latter three outcomes was similar
in participants with and without diabetes (Table 3).
Median time from measurement of LVEF to randomization was
48 days (Q1–Q3 14–130). A total of 3962 (84%) patients had
their LVEF measured within 6 months prior to randomization. The
incremental increase in risk of clinical outcomes with decreasing
LVEF was also consistent in both those who had LVEF measured
≤6 months prior to randomization and in those who had LVEF
measured >6 months prior to randomization (Table 3).
Effect of dapagliflozin, compared
with placebo, on hospitalization
and mortality outcomes, according
to baseline left ventricular ejection
fraction
For each of the hospitalization and mortality outcomes examined,
the event rate was lower in patients receiving dapagliflozin, than in
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to left ventricular ejection fraction
<26%
(n = 1143)
26–30%
(n = 1018)
31–35%
(n = 1187)
>35%
(n = 1396)
P-value
for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LVEF (%) 22.4± 3.7 28.8±1.4 33.7±1.4 38.4±1.4 <0.001
Age (years) 64.2±11.3 66.0±10.8 66.8±10.6 68.1±10.5 <0.001
Women 230 (20.1) 215 (21.1) 277 (23.3) 387 (27.7) <0.001
Region <0.001
Europe 406 (35.5) 398 (39.1) 556 (46.8) 794 (56.9)
Asia/Pacific 283 (24.8) 262 (25.7) 258 (21.7) 293 (21.0)
North America 241 (21.1) 140 (13.8) 171 (14.4) 125 (9.0)
Latin America 213 (18.6) 218 (21.4) 202 (17.0) 184 (13.2)
Race <0.001
White 728 (63.7) 695 (68.3) 857 (72.2) 1053 (75.4)
Black 104 (9.1) 43 (4.2) 48 (4.0) 31 (2.2)
Asian 288 (25.2) 266 (26.1) 263 (22.2) 299 (21.4)
Other 23 (2.0) 14 (1.4) 19 (1.6) 13 (0.9)
Heart rate (bpm) 72.6±12.4 71.5±11.6 70.9±11.5 71.0±11.3 0.001
SBP (mmHg) 116.5±15.1 120.0±15.3 123.4±16.7 126.1±16.2 <0.001
DBP (mmHg) 71.9± 10.1 72.9±10.7 74.0±10.7 74.8±10.2 <0.001
BMI (kg/m2) 27.7± 6.4 27.8± 5.8 28.4± 5.9 28.6± 5.8 <0.001
Medical history
Hypertension 720 (63.0) 743 (73.0) 907 (76.4) 1153 (82.6) <0.001
Diabetes 453 (39.6) 432 (42.4) 485 (40.9) 613 (43.9) 0.062
Myocardial infarction 455 (39.8) 485 (47.6) 538 (45.3) 614 (44.0) 0.123
Atrial fibrillation 384 (33.6) 352 (34.6) 462 (38.9) 620 (44.4) <0.001
Stroke 103 (9.0) 104 (10.2) 107 (9.0) 152 (10.9) 0.210
COPD 137 (12.0) 111 (10.9) 143 (12.1) 194 (13.9) 0.088
Features of HF
HF aetiology <0.001
Ischaemic 548 (47.9) 575 (56.5) 703 (59.2) 848 (60.7)
Non-Ischaemic 493 (43.1) 373 (36.6) 393 (33.1) 428 (30.7)
Unknown 102 (8.9) 70 (6.9) 91 (7.7) 120 (8.6)
Prior HF hospitalization 577 (50.5) 486 (47.7) 548 (46.2) 640 (45.8) 0.016
KCCQ-TSS 77 [59–92] 79 [58–94] 79 [58–92] 76 [57–92] 0.265
NYHA class 0.995
II 754 (66.0) 712 (69.9) 805 (67.8) 932 (66.8)
III/IV 389 (34.0) 306 (30.1) 382 (32.2) 464 (33.2)
NT-proBNP (pg/mL) 1827 [1055–3385] 1551 [886–2806] 1317 [798–2353] 1275 [790–2232] <0.001
eGFR (mL/min/1.73 m2) 67.3±19.9 64.8±19.2 65.9±19.7 65.2±18.9 0.062
Creatinine (μmol/L) 105.1± 30.5 106.6± 31.8 104.3± 30.4 102.5± 29.2 0.006
Haemoglobin (g/L) 136.6±15.9 135.7±16.0 135.0±16.2 135.0±16.6 0.005
Treatment
Diuretic 1100 (96.2) 960 (94.3) 1098 (92.5) 1275 (91.3) <0.001
ACEI 590 (51.6) 582 (57.2) 655 (55.2) 834 (59.7) <0.001
ARB 283 (24.8) 269 (26.4) 329 (27.7) 426 (30.5) 0.001
ARNI 188 (16.4) 118 (11.6) 130 (11.0) 72 (5.2) <0.001
Any RAS blockera 1051 (92.0) 958 (94.1) 1109 (93.4) 1324 (94.8) 0.009
Beta-blocker 1100 (96.2) 979 (96.2) 1146 (96.5) 1333 (95.5) 0.403
MRA 855 (74.8) 755 (74.2) 841 (70.9) 919 (65.8) <0.001
Digoxin 265 (23.2) 207 (20.3) 193 (16.3) 222 (15.9) <0.001
Ivabradine 66 (5.8) 51 (5.0) 61 (5.1) 50 (3.6) 0.014
PCI 346 (30.3) 374 (36.7) 404 (34.0) 500 (35.8) 0.020
CABG 178 (15.6) 177 (17.4) 197 (16.6) 247 (17.7) 0.231
CRT 116 (10.1) 86 (8.4) 90 (7.6) 62 (4.4) <0.001
ICD 358 (31.3) 250 (24.6) 216 (18.2) 129 (9.2) <0.001
Diabetes medicationsb
Biguanide 230 (50.8) 221 (51.2) 261 (53.8) 304 (50.0) 0.828
DPP-4 inhibitor 68 (15.0) 67 (15.5) 76 (15.7) 99 (16.2) 0.614
GLP-1 analogues 7 (1.6) 5 (1.2) 4 (0.8) 5 (0.8) 0.225
Sulfonylurea 93 (20.5) 105 (24.3) 107 (22.1) 133 (21.7) 0.919
Insulin 112 (24.7) 122 (28.2) 144 (29.7) 162 (26.4) 0.554
Values are shown as mean ± standard deviation, n (%), or median [interquartile range].
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CABG, coronary artery bypass graft; COPD,
chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; DPP, dipeptidyl peptidase; eGFR, estimated glomerular filtration rate; GLP, glucagon-like
peptide; HF, heart failure; ICD, implantable cardioverter-defibrillator; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RAS, renin–angiotensin
system; SBP, systolic blood pressure.
aAny patient on ACEI/ARB/ARNI.
bOnly in patients with a medical history of diabetes (n = 1983).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Clinical outcomes according to baseline left ventricular ejection fraction (LVEF). Restricted cubic spine analyses of clinical outcomes
according to baseline LVEF: primary composite outcome, cardiovascular death, heart failure (HF) hospitalization/urgent visit for HF, and all-cause
death. Figures have been restricted to 10–40% LVEF but the results are derived from models based on the entire spectrum of LVEF in DAPA-HF.
HR, hazard ratio.
those assigned to placebo, across all the LVEF categories (Table 2
and online supplementary Figure S2).
The effect of dapagliflozin was consistent across the range of
LVEF for the primary composite outcome [P-value for interaction:
0.762 (categorical) and 0.205 (continuous)], cardiovascular death
[P-value for interaction: 0.974 (categorical) and 0.997 (continuous)]
and HF hospitalization or urgent visit for HF [P-value for inter-
action: 0.161 (categorical) and 0.150 (continuous)] and all-cause
death [P-value for interaction: 0.866 (categorical) and 0.962 (con-
tinuous)] (Table 2 and Figure 2).
The benefit of dapagliflozin over placebo for these outcomes
was also consistent in patients with and without diabetes anal-
ysed separately, across the range of LVEF studied (online sup-
plementary Table S2 and Figure S5). Similarly, beneficial effects of
dapagliflozin also remained constant across the range of LVEF
regardless of the time of measurement of LVEF (online supplemen-
tary Figure S6).
The favourable effect of dapagliflozin on the composite of HF
hospitalization (first and repeat) and cardiovascular death was also
consistent across the spectrum of LVEF studied (in the overall ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. cohort, and in participants with and without diabetes analysed
separately).
Because the absolute risk of events was highest in patients in
the lowest LVEF category, the absolute benefit of dapagliflozin was
larger in patients with a lower LVEF. For example, applying the
overall relative risk reduction of 26% to patients with a LVEF of
<26% yielded an absolute risk reduction of 54 fewer patients with
an event per 1000 person-years of follow-up, compared with 31
per 1000 person-years of follow-up in the LVEF >35% category.
Relationship between baseline left
ventricular ejection fraction and change
in Kansas City Cardiomyopathy
Questionnaire total symptom score
The mean change in KCCQ-TSS in the placebo group was similar
in each of the LVEF categories analysed (Table 2). The propor-
tion of patients in the placebo group exhibiting a ≥5 point increase
(improvement) in KCCQ-TSS was similar across LVEF categories.
The same was true for the proportion of patients reporting a
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Dapagliflozin effects by left ventricular ejection fraction 7
Ta
bl
e
3
C
ha
ng
e
in
ri
sk
o
fc
lin
ic
al
o
ut
co
m
es
pe
r
5-
po
in
t
de
cr
ea
se
in
ba
se
lin
e
le
ft
ve
nt
ri
cu
la
r
ej
ec
ti
o
n
fr
ac
ti
o
n
–
ov
er
al
l,
by
di
ab
et
es
st
at
us
an
d
by
ti
m
e
o
fl
ef
t
ve
nt
ri
cu
la
r
ej
ec
ti
o
n
fr
ac
ti
o
n
m
ea
su
re
m
en
t
O
ve
ra
ll
(n
=
47
44
)
N
o
di
ab
et
es
(n
=
26
05
)
D
ia
be
te
s
(n
=
21
39
)
LV
E
F
m
ea
su
re
d
≤
6
m
o
nt
hs
be
fo
re
ra
nd
o
m
iz
at
io
n
(n
=
39
62
)a
LV
E
F
m
ea
su
re
d
>
6
m
o
nt
hs
be
fo
re
ra
nd
o
m
iz
at
io
n
(n
=
77
9)
a
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Pr
im
ar
y
ou
tc
om
e
1
.1
8
(1
.1
3
–
1
.2
4)
<
0.
00
1
1
.1
7
(1
.1
0
–
1
.2
6)
<
0.
00
1
1
.2
0
(1
.1
2
–
1
.2
7)
<
0.
00
1
1
.1
9
(1
.1
3
–
1
.2
5)
<
0.
00
1
1
.1
4
(1
.0
2
–
1
.2
7)
0.
01
8
C
V
de
at
h
or
H
F
ho
sp
ita
liz
at
io
n
1
.1
8
(1
.1
3
–
1
.2
4)
<
0.
00
1
1
.1
9
(1
.1
1
–
1
.2
7)
<
0.
00
1
1
.1
8
(1
.1
1
–
1
.2
6)
<
0.
00
1
1
.1
8
(1
.1
3
–
1
.2
5)
<
0.
00
1
1
.1
5
(1
.0
3
–
1
.2
8)
0.
01
5
C
V
de
at
h
1
.2
0
(1
.1
3
–
1
.2
8)
<
0.
00
1
1
.2
0
(1
.1
0
–
1
.3
2)
<
0.
00
1
1
.2
0
(1
.1
1
–
1
.3
1
)
<
0.
00
1
1
.2
2
(1
.1
4
–
1
.3
0)
<
0.
00
1
1
.0
9
(0
.9
4
–
1
.2
7)
0.
23
4
H
F
ho
sp
ita
liz
at
io
n/
ur
ge
nt
vi
si
tb
1
.2
0
(1
.1
4
–
1
.2
7)
<
.0
.0
01
1
.1
6
(1
.0
6
–
1
.2
6)
0.
00
1
1
.2
4
(1
.1
5
–
1
.3
4)
<
0.
00
1
1
.2
0
(1
.1
2
–
1
.2
7)
<
0.
00
1
1
.2
0
(1
.0
5
–
1
.3
7)
0.
00
8
H
F
ho
sp
ita
liz
at
io
n
1
.2
0
(1
.1
3
–
1
.2
7)
<
0.
00
1
1
.1
7
(1
.0
7
–
1
.2
8)
<
0.
00
1
1
.2
2
(1
.1
3
–
1
.3
2)
<
0.
00
1
1
.1
9
(1
.1
2
–
1
.2
7)
<
0.
00
1
1
.2
1
(1
.0
6
–
1
.3
9)
0.
00
6
To
ta
lH
F
ho
sp
ita
liz
at
io
n/
C
V
de
at
h
1
.2
2
(1
.1
6
–
1
.2
8)
<
0.
00
1
1
.1
9
(1
.1
0
–
1
.2
8)
<
0.
00
1
1
.2
4
(1
.1
5
–
1
.3
3)
<
0.
00
1
1
.2
2
(1
.1
5
–
1
.2
9)
<
0.
00
1
1
.1
9
(1
.0
5
–
1
.3
5)
0.
00
5
A
ll-
ca
us
e
de
at
h
1
.1
3
(1
.0
7
–
1
.2
0)
<
0.
00
1
1
.1
5
(1
.0
6
–
1
.2
4)
0.
00
1
1
.1
2
(1
.0
4
–
1
.2
1
)
0.
00
4
1
.1
5
(1
.0
8
–
1
.2
2)
<
0.
00
1
1
.0
3
(0
.9
0
–
1
.1
8)
0.
66
3
C
V,
ca
rd
io
va
sc
ul
ar
;H
F,
he
ar
t
fa
ilu
re
;L
V
EF
,l
ef
t
ve
nt
ri
cu
la
r
ej
ec
tio
n
fr
ac
tio
n.
N
um
be
rs
re
pr
es
en
t
ha
za
rd
ra
tio
w
ith
95
%
co
nfi
de
nc
e
in
te
rv
al
fo
r
ea
ch
5-
po
in
t
de
cr
ea
se
in
LV
EF
.R
at
e
ra
tio
fo
r
to
ta
lH
F
ho
sp
ita
liz
at
io
n/
C
V
de
at
h.
H
az
ar
d
ra
tio
s
(a
nd
re
la
tiv
e
ri
sk
)
ad
ju
st
ed
fo
r
ra
nd
om
iz
ed
tr
ea
tm
en
t,
pr
ev
io
us
H
F
ho
sp
ita
liz
at
io
n
at
ba
se
lin
e
(e
xc
ep
t
al
l-c
au
se
de
at
h)
an
d
st
ra
tifi
ed
by
di
ab
et
es
st
at
us
.
a D
at
e
of
LV
EF
m
ea
su
re
m
en
t
w
as
se
t
to
m
is
si
ng
fo
r
th
re
e
pa
tie
nt
s.
b
R
eq
ui
ri
ng
in
tr
av
en
ou
s
th
er
ap
y
fo
r
H
F.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. ≥5 point decrease (deterioration) in KCCQ-TSS. These findings
were similar in patients with and without diabetes (online supple-
mentary Table S2).
Effect of dapagliflozin, compared
with placebo, on change in Kansas City
Cardiomyopathy Questionnaire total
symptom score, according to baseline
left ventricular ejection fraction
The mean increase (improvement) in KCCQ-TSS with
dapagliflozin, compared with placebo, was similar in each of
the LVEF categories (P-value for interaction: 0.607) (Table 2; online
supplementary Figure S1). Compared with placebo, more patients
treated with dapagliflozin showed a ≥5 point improvement, and
fewer a ≥5 point deterioration, in each of the LVEF categories
analysed. These findings were similar in patients with and without
diabetes.
Relationship between baseline left
ventricular ejection fraction
and pre-specified safety outcomes
There was no significant difference in the proportion of those
on placebo who discontinued the study due to any reason across
the LVEF categories (Table 4 and online supplementary Table S3).
Similarly, no difference was seen in the proportion of patients on
placebo with adverse events due to renal causes, fractures, ampu-
tation, or major hypoglycaemic events. However, the proportion of
patients with volume depletion was higher in the lower LVEF cate-
gories. A fall in SBP among those on placebo during follow-up was
slightly higher in those with LVEF >35% but no such observation
was made with respect to change in creatinine (Table 4).
Effect of dapagliflozin, compared
with placebo, on pre-specified safety
outcomes, according to baseline left
ventricular ejection fraction
There was no significant difference in the proportion of patients
who discontinued for any reason or those who discontinued due to
an adverse event between the treatment groups in any of the LVEF
categories, including due to volume depletion (P-value for interac-
tion: 0.548 and 0.544, respectively) (Table 4). Similarly, no difference
in the magnitude of change in SBP or creatinine during follow-up
was seen between the treatment groups in each LVEF category
(P-value for interaction: 0.529 and 0.258, respectively) (Table 4).
Discussion
In this analysis of 4744 patients with HFrEF in DAPA-HF, the
baseline characteristics of patients varied across the spectrum
of LVEF, as expected. Patients with and without diabetes also
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Effect of dapagliflozin on clinical outcomes according to baseline left ventricular ejection fraction (LVEF). Fractional polynomial
analyses showing the effect of dapagliflozin treatment on clinical outcomes across the range of LVEF: primary composite outcome, cardiovascular
death, heart failure (HF) hospitalization/urgent visit for HF, and all-cause death. Figures have been restricted to 10-40% LVEF but the results
are derived from models based on the entire spectrum of LVEF in DAPA-HF. HR, hazard ratio.
differed as expected, but these differences were consistent across
the range of LVEF studied. LVEF was a powerful predictor of
the risk of hospitalization and death overall and in patients with
and without diabetes separately. The benefit of dapagliflozin on
mortality/morbidity outcomes was not modified by baseline LVEF,
irrespective of diabetes status. By contrast, symptom severity at
baseline did not vary according to LVEF. Symptoms improved to a
similar extent with dapagliflozin across the range of LVEF studied.
The benefit of dapagliflozin on symptoms, in relation to LVEF, was
consistent in patients with and without diabetes.
As in previous studies, patients with lower LVEF were younger,
more likely to be male, had fewer comorbidities and less likely
to have an ischaemic aetiology. Although there was no difference
in NYHA class across the LVEF categories, NT-proBNP was
substantially higher in patients in the lowest, compared with the
highest, LVEF category (despite a much higher prevalence of atrial
fibrillation in the latter).
We found that each 5-point decrement in baseline LVEF was
associated with a 20% higher risk of cardiovascular death, a 20%
higher risk of HF hospitalization and a 13% higher risk of all-cause .
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. death. These findings are very similar to what was reported in
the Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure trial
(PARADIGM-HF), where the corresponding increments in risk
for each 5-point reduction in LVEF were 17%, 17% and 14%,
respectively.9 These findings are also consistent with earlier studies
assessing the relationship between LVEF and outcomes in HFrEF.1
The relative increase in risk of death and hospitalization for a
5-point decrement in baseline LVEF was similar in participants with
and without diabetes, although the absolute risk for a given LVEF
was higher in individuals with diabetes.
While the benefit of effective therapies for HFrEF has gener-
ally been found to be similar across the LVEF spectrum, the range
of LVEF in such analyses has been limited as few landmark trials
included patients with a LVEF >35%.10–24 Furthermore, several
earlier studies suggested greater benefit of therapy at the lower
end of the LVEF spectrum.6 However, we found that, compared
with placebo, the benefit of dapagliflozin on the primary and sec-
ondary mortality/morbidity outcomes was consistent across the
range of LVEF studied. This benefit according to LVEF was also
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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consistent in patients with and without diabetes. Consequently,
patients with a low LVEF obtained a particularly large absolute bene-
fit from dapagliflozin because individuals with a low LVEF, especially
if diabetic, were at much greater absolute risk than patients with a
higher LVEF. Whether the benefit of SGLT2 inhibition will extend
to patients with HF and mid-range/mildly reduced and frankly pre-
served ejection fraction remains to be determined, especially in
patients without type 2 diabetes. Retrospective subgroup analy-
ses of prior trials with SGLT2 inhibitors in individuals with type
2 diabetes and predominantly atherosclerotic cardiovascular dis-
ease (or cardiovascular risk factors) have suggested that these
drugs may be beneficial in patients with HFpEF, but these find-
ings are far from conclusive.25,26 This question will be answered,
definitively, by the ongoing EMPagliflozin outcomE tRial in Patients
With chrOnic heaRt Failure With Preserved Ejection Fraction
(EMPEROR-Preserved; NCT03057951) and Dapagliflozin Evalua-
tion to Improve the LIVEs of Patients With PReserved Ejection
Fraction Heart Failure (DELIVER; NCT03619213) trials, both of
which have enrolled patients with LVEF >40%.27
Two novel aspects of this study were the analysis of symptoms
and the analysis of recurrent events, in relation to baseline LVEF,
and according to diabetes status, and the effect of treatment on
these outcomes. The two large pharmacological therapy trials that
have reported the effect of treatment on KCCQ in HFrEF have not
described the relationship between KCCQ score and LVEF or the
effect of therapy according to LVEF.28,29 However, in the CHARM
program, there was no clear association between LVEF and a
different patient-reported outcome, a finding that is consistent
with the current observations in DAPA-HF.30 In addition, KCCQ
scores are similar in patients with HFrEF and HFpEF, which also
suggests little correlation between this patient-reported outcome
and LVEF.31 Interestingly, change in KCCQ-TSS from baseline was
also independent of LVEF, and similar in patients with and without
diabetes. The reason why symptoms and health-related quality
of life correlate poorly with LVEF is uncertain but, importantly,
dapagliflozin improved symptoms as well as other outcomes. This
beneficial effect of dapagliflozin, whether assessed as mean change
in KCCQ-TSS, or the proportion of patients with a clinically
meaningful change (≥5 points), was similar across LVEF categories,
both overall, and in patients with and without diabetes.
Analysis of recurrent non-fatal, along with fatal, events may pro-
vide a better quantification of the full burden of HF, compared
with conventional time-to-first event analysis.32–34 Repeat admis-
sions are distressing for patients, a marker of disease progression,
represent an adverse prognostic change, and are expensive. Like-
wise, analysis of recurrent events is a rigorous test of the effect
of treatment, as it measures persistence of pharmacological effect
and adherence (e.g. treatment discontinuation after a first event
will reduce any effect of therapy on subsequent events).35 That this
type of analysis reflects disease burden is clearly shown by the very
high event rates compared with time-to-first event analysis in the
present analysis, e.g. reaching almost 40 per 1000 person-years
of follow-up for HF hospitalization and cardiovascular death in
patients with diabetes in the lowest LVEF category. However, the
benefit of dapagliflozin was almost identical in the recurrent events
and time-to-first analyses, and the relative risk reduction with ..
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.. dapagliflozin was consistent across the range of LVEF examined
overall, and in patients with and without diabetes.
As has been shown previously, patients in DAPA-HF with lower
LVEF were more likely to have adverse events related to volume
depletion but no difference was seen between the treatment
groups even in those with the lowest LVEF, allaying concerns of a
potentially greater risk of volume depletion in HF patients in whom
diuretic use is almost universal.36,37 The only other significant
observation among the safety outcomes was the larger fall in SBP
in the highest LVEF category but this was most likely a function of
their higher baseline SBP.
Study limitations
Our study had several limitations. This was a post hoc analysis in
which patients were divided into arbitrary, clinically relevant LVEF
categories.1,6,7 Additionally, LVEF was measured using different
methods at different sites and there was no core laboratory.
Time of measurement of LVEF before randomization also varied,
but this variation did not affect outcomes. We did not have
information on the method used to measure LVEF. There was also
digit preference in the reporting of LVEF measurements, as often
found.1,9 SBP below 95 mmHg and eGFR below 30 mL/min/1.73 m2
were exclusion criteria in DAPA-HF and this may have skewed the
characteristics of our patients in the lowest LVEF category, more
of which might have been expected to have lower SBP and worse
renal function.
Conclusion
Left ventricular ejection fraction at baseline was a significant
predictor of hospitalization and mortality (but not symptoms) in
patients with HFrEF enrolled in DAPA-HF. LVEF did not modify the
beneficial effect of dapagliflozin on mortality/morbidity outcomes,
or symptoms, in patients with HFrEF overall, and in those with and
without diabetes separately.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Placebo corrected mean change in Kansas City Car-
diomyopathy Questionnaire total summary score at 8 months
according to left ventricular ejection fraction – overall and accord-
ing to diabetic status.
Figure S2. Effect of randomized treatment on clinical outcomes,
according to left ventricular ejection fraction: primary composite
outcome, cardiovascular death, heart failure hospitalization/urgent
visit, and all-cause death.
Figure S3. Restricted cubic spine analyses of clinical outcomes
according to baseline left ventricular ejection fraction and diabetes
status: primary composite outcome, cardiovascular death, heart
failure hospitalization/urgent visit, and all-cause death.
Figure S4. Effect of randomized treatment on clinical outcomes,
according to left ventricular ejection fraction and diabetes status:
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Dapagliflozin effects by left ventricular ejection fraction 11
primary composite outcome, cardiovascular death, heart failure
hospitalization/urgent visit, and all-cause death.
Figure S5. Fractional polynomial analyses showing the effect of
dapagliflozin treatment on clinical outcomes across the range of
left ventricular ejection fraction, according to diabetes status:
primary composite outcome, cardiovascular death, heart failure
hospitalization/urgent visit, and all-cause death.
Figure S6. Forest plot showing the hazard ratios (95% confidence
interval) for the major clinical outcomes in DAPA-HF according to
left ventricular ejection fraction (LVEF) and the time of measure-
ment of LVEF (≤6 months vs. >6 months)
Table S1. Baseline characteristics according to left ventricular
ejection fraction and diabetes status at baseline.
Table S2. Clinical outcomes according to left ventricular ejection
fraction and diabetes status at baseline.
Table S3. Safety outcomes according to left ventricular ejection
fraction and diabetes status at baseline.
Table S4. Baseline characteristics according to left ventricular
ejection fraction and randomization arm.
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